[Skip to Content]

DMO

NICE rapid review of previous technology appraisal – intravitreal ranibizumab with DMO

College Statement The National Institute of Clinical Excellence (NICE) has completed a rapid review of the previous technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema. The new guidance document on ranibizumab for diabetic macular oedema, (TA274), published on 27 February 2013, recommends that patients with DMO can be commenced